Latest Posts:
Search for:
Tag

Transactions

Browsing
In Pharmaceuticals & Biotech

Impact of MFN Pricing on Transactions

by , , , and 1 Min Read

Recent US efforts to introduce Most Favored Nation (MFN) drug pricing are creating new layers of uncertainty for transactions involving the commercialization of prescription medicines in the US. These policies – designed to align US drug prices with the lowest prices available in comparable countries – have the potential to reshape deal economics, launch strategies, and global pricing structures. This article outlines the current MFN policy landscape and explores how these developments may affect both…

Read More
In Pharmaceuticals & Biotech

Manufacturing Site Divestitures: Best Practices for Successful Execution

by , , and 11 Mins Read

Pharmaceutical companies are increasingly outsourcing complex manufacturing activities to contract development and manufacturing organizations, or CDMOs. This enables pharmaceutical companies to streamline their operations and redeploy capital toward research and development activities. At the same time, the CDMO industry is booming, with many analysts predicting continued rapid growth. CDMOs need more capacity, and they need it quickly. As a result of these trends, many pharmaceutical companies are engaging in an increasing number of transactions in…

Read More
In Medical Devices

Mitigating Risk in Life Sciences Acquisitions

by 8 Mins Read

In the race to innovate, life sciences companies are betting big on M&A, but navigating the risks requires smarter deal structures Big pharmaceutical companies facing patent cliffs. MedTech companies seeking access to the latest AI technologies. Across the life sciences industry, companies have strong incentives to use M&A to grow their product pipelines, enhance their existing product offerings, and gain access to new markets. But, at what cost? Less than half of phase II clinical…

Read More